LC
SWTX

Lindbrook Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Lindbrook Capital’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$10.9K Buy
246
+106
+76% +$4.88K ﹤0.01% 1612
2024
Q4 		$5.06K Buy
140
+34
+32% +$1.19K ﹤0.01% 1984
2024
Q3 		$3.4K Buy
106
+14
+15% +$523 ﹤0.01% 2167
2024
Q2 		$3.47K Sell
92
-4
-4% -$168 ﹤0.01% 2153
2024
Q1 		$4.72K Buy
96
+4
+4% +$185 ﹤0.01% 1917
2023
Q4 		$3.36K Buy
92
+44
+92% +$1.15K ﹤0.01% 2076
2023
Q3 		$1.11K Buy
48
+30
+167% +$820 ﹤0.01% 2330
2023
Q2 		$472 Sell
18
-137
-88% -$3.6K ﹤0.01% 2526
2023
Q1 		$3.99K Buy
155
+60
+63% +$1.75K ﹤0.01% 1940
2022
Q4 		$2.47K Buy
95
+13
+16% +$320 ﹤0.01% 2150
2022
Q3 		$2K Buy
82
+72
+720% +$2.06K ﹤0.01% 2148
2022
Q2 		$0 Buy
+10
New +$366 ﹤0.01% 2759
2021
Q2 		– Sell
-100
Closed -$7K – 2000
2021
Q1 		$7K Buy
+100
New +$7.83K ﹤0.01% 1168

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Lindbrook Capital's SWTX Position: Q1 2025 in Review

Lindbrook Capital increased its SpringWorks Therapeutics (SWTX) stake by 76% in Q1 2025, buying an estimated $4.88K and bringing the position to 246 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1612.

Lindbrook Capital first reported a position in SWTX in Q1 2021 and has held it in 13 quarters since. 306 funds tracked by Wall St. Rank hold SWTX as of Q1 2025.

  • Lindbrook Capital held 246 shares of SpringWorks Therapeutics worth $10.9K as of Q1 2025.
  • Lindbrook Capital bought 106 SpringWorks Therapeutics shares in Q1 2025, an estimated $4.88K.
  • SpringWorks Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1612 holding.
  • Lindbrook Capital first reported a position in SpringWorks Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • 306 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.